Thermo Fisher Scientific (TMO) EBT (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBT for 18 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 12.58% year-over-year to $1.9 billion; the trailing twelve-month figure through Jun 2026 stood at $7.6 billion (up 8.91% YoY), and the FY2025 full-year result was $7.3 billion, up 3.85% from the prior year.
• EBT grew to $1.9 billion in Q2 2026 per TMO's latest filing, from $1.7 billion in the prior quarter.
• Across five years, EBT topped out at $2.5 billion in Q2 2022 and bottomed at $1.4 billion in Q2 2023.
• Historically, EBT has averaged $1.8 billion across 5 years, with a median of $1.8 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: EBT sank 46.34% in 2023, then climbed 23.43% in 2024.
• Over 5 years, EBT stood at $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then rose by 11.55% to $1.9 billion in 2024, then gained by 10.92% to $2.2 billion in 2025, then slipped by 10.64% to $1.9 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $1.9 billion, $1.7 billion, and $2.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.